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ABSTRACT 
 
Heparin, which is a glycosaminoglycan, was originally found and used as an anti-
coagulant. But it has also been implicated in binding to vascular cells, down-regulating 
their proliferation and inflammation responses at least through MAPK pathways [1], [2] 
by employing the PKG pathway [3]. Previous studies have indicated that heparin 
increases eNOS(endothelial nitric oxide synthase) activity in bovine endothelial cells. 
However, the precise mechanism has not been fully elucidated. 
Immunoprecipitation in endothelial cells by using monoclonal heparin binding blocking 
antibodies identified a protein as a gene product of TMEM184A, to be a putative heparin 
receptor [4].  
In this study, we investigated the impact of heparin treatment on eNOS's activation and 
the role of eNOS in heparin signaling. The results indicate that heparin induced 
phosphorylation and activation of eNOS. eNOS was internalize to perinuclear region in a 
TMEM184A dependent manner in response to heparin. We also examined how heparin 
treatment lead to phosphorylation of eNOS and confirmed that TMEM184A and Ca2+ 
were required to mediate heparin elicited eNOS phosphorylation. Integrin and TRPV4 are 
demonstrated to be potentially involved in this activation process on eNOS.  
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1.1 Heparin and its signaling 
Heparin, which is a glycosaminoglycan, was originally found and used as an anti-
coagulant. But it has also been implicated in binding to vascular cells, down-regulating 
their proliferation and inflammation responses at least through MAPK pathways [1], [2] 
by employing the PKG pathway [18]. However, detailed and comprehensive mechanisms 
for such functions of heparin remain unclear.  
In vivo data suggest that low-anticoagulant heparin can inhibit adhesion of leukocytes to 
endothelium [5] and the binding is a key response to inflammation. Proteolytic enzymes 
and toxic oxygen radicals are released following excessive leukocyte activation and 
consequently lead to vascular and tissue damage.  
P-selectin is mainly expressed on activated endothelial cells and responsible for loose 
association between neutrophils and the endothelium. This interaction is effectively 
inhibited by heparin [6]. When neutrophils were incubated with heparin or low 
anticoagulant derivatives, heparin was able to inhibit adhesion of these cells to 
endothelial cell monolayers that are induced to produce P-selectin [7].  
The ability of heparin to bind chemokines, cytokines and other mediators released from 
inflammatory cells is also considered to contribute to heparin's anti-inflammatory effects 
because such binding inhibits these pro-inflammatory molecules [8] from binding with 
the respective receptors.  
The anti-inflammatory effects of heparin are also observed on cultured vascular cells. 
Heparin is observed to bind endothelial cells and inhibit inflammation via NF-κB and 
stress kinases pathways [12]. NF-κB regulates many genes that increase production of 
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inflammatory and immune response genes, including interleukin-6 and 8, ICAM-1, L- 
and P-selectins [10]. Heparin has been thought to bind to and be endocytosed into the 
cytosolic compartment of endothelial cells and VSMCs [11] and prevent NF-κB from 
translocating to nucleus [12]. 
Heparin is also found to bind [13] and reduce the growth of VSMCs [14], decrease 
MAPK signaling [15] and thereby inhibits early proto-oncogene, AP-1, promoters 
controlling gene expression, and the G1 phase of the cell cycle. Heparin treatment 
reduces expression of c-fos and c-myc in serum, PDGF, or bFGF activated cells [13] and 
down-regulates cyclin dependent kinase 2 activity by up-regulating levels of p27kip1 
[16]. Heparin also promotes synthesis of MKP-1 in VSMCs that regulates activity of 
ERK [17].  
Published data indicate that protein kinase G signaling is at least partially involved in 
heparin's anti-proliferation effects on VSMCs. PKG inhibitors down-regulate heparin-
induced ERK, Elk-1 inactivation, MKP-1 synthesis, and eliminate heparins' effect on 
bromodeoxyuridine incorporation. Knocking down PKG also decreases heparin 
responses in activated VSMCs [18]. Moreover, the cGMP level is increased transiently 
after heparin treatment [18]. 
Immunoprecipitation in endothelial cells by using monoclonal heparin binding blocking 
antibodies identified a protein as a gene product of TMEM184A, to be a putative heparin 
receptor[4].  
 
1.2 Heparin signaling and eNOS 
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1.2.1 Introduction on eNOS 
The messenger molecule nitric oxide (NO) is important in regulating cardiovascular 
physiology including vasodilators, antioxidants, and platelet inhibitors. NOSs are 
enzymes that are responsible for biosynthesis of NO and L-citrulline from L-arginine. 
Endothelial nitric oxide synthase (eNOS) is the predominant NOS isoform in 
synthesizing most of vascular nitric oxide (NO), which is an upstream factor that can 
induce PKG signaling events. eNOS has been implicated in heparin signaling events and 
consequently protecting vascular functions [19]. 
There are 3 well-characterized NOS isoforms that can be differentiated by their 
subcellular localization and regulatory mechanisms, the eNOS (endothelial), nNOS 
(neuronal), and iNOS (inducible) isoforms.  
nNOS (neuronal) is mostly expressed in peripheral and central neurons and in various 
other cell types. eNOS (endothelial) is largely present in endothelial cells and also 
expressed in vascular smooth muscle cells (VSCMs), cardiac myocytes and blood 
platelets. eNOS and nNOS are constitutively expressed while their activity is controlled 
by calcium levels, phosphorylation and through other mechanisms. eNOS is the 
predominant NOS isoform in synthesizing most of vascular nitric oxide (NO), which is 
an upstream factor that can induce PKG signaling events. Heparin has been implicated in 
regulating eNOS5 and consequently protecting vascular functions [19].  
1.2.2 Heparin and eNOS 
Numerous studies support the hypothesis that heparin and its derivatives can regulate 
eNOS and can thereby protect endothelial function. Both heparin and its non-anti-
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coagulant derivative, N-acetyl heparin, dose-dependently increase eNOS activity by 
promoting citrulline and nitric oxide metabolite formation in BAOECs [20]. In vivo 
experiments suggest that heparin can increase NOS activity and cGMP levels in lung at 
both three days and three weeks [19].  
Moreover, eNOS might be mediating heparin's signaling because it is a upstream factor 
of PKG, and PKG has been shown to be involved in heparin signaling [18]. Activation of 
eNOS leads to production of NO which stimulates soluble guanylate cyclase (sGC) and 
that sGC results in accumulation of cGMP which leads to activation of the PKG [21]. 
Therefore, heparin treatment might affect PKG and cGMP through regulation of eNOS.  
However, heparin has also been reported to suppress Akt at least in some cell types. 
Treatment with heparin leads to significant reduction in cell viability and a significant 
decrease in phosphorylated Akt at 24 hrs in SCC cell lines [22]. Akt is a serine/threonine 
protein kinase that plays important roles in regulating many biological processes, 
including proliferation, cell growth and apoptosis. Akt is able to phosphorylate eNOS at 
ser 1177 to activate it. There have also been studies showing that heparin can compete 
with endogenous heparan sulfate and disrupt interactions between PECAM-1 and Gaq/11 
[23] and thereby may decrease the activity of Akt. According to these results, heparin 
might also down-regulate eNOS by decreasing its phosphorylation at p1177 at some time 
after treatment in some cell types.  
1.2.3 Introduction on eNOS Regulation 
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eNOS is regulated through various cellular events including post-translational 
modification, calcium wave stimulation, association or dissociation with its binding 
proteins. The pathways are illustrated in Figure 1 [24]. 
Intracellular Ca2+ increases can cause calmodulin binding to nNOS and eNOS and hence 
facilitate electron transfer from the reductase domain to the oxygenase domain of the 
NOS to synthesize NO. NO consequently activates soluble guanylate cyclase (sGC) and 
downstream signaling pathways. eNOS has vasoprotective and anti-atheroslerosis 
functions contributing to controlling vascular tone, angiogenesis, and other effects.  
Internal electron transfer is required for the synthesis of NO by eNOS. The binding 
between Ca2+ and calmodulin regulates internal electron transfer through redox-linked 
conformational changes. CaM binds to eNOS at increased intracellular Ca2+ 
concentration [25] and couples electron transfer between the reductase domain and the 
oxygenase domain [26].  
eNOS can be regulated through multiple post- translational modifications including 
acylation, nitrosylation, and phosphorylation which can dynamically regulate not only 
activity but also its localization and its interaction with other cellular elements.  
A major principle of post-translational regulation of eNOS activity is through 
phosphorylation, multi-site phosphorylation, and dephosphorylation at key serine and 
threonine residues in eNOS. Stimulatory phosphorylation loci include Ser1177 [27], Ser 
617, and Ser 635, while inhibitory sites are Thr 495 and Ser 116 [28].   
Most of the phosphorylation events control activity of eNOS by affecting affinity 
between calmodulin and eNOS. For example, phosphorylation at Ser 1177 in eNOS 
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inhibits dissociation of calmodulin from eNOS and enhances intermodule electron 
transfer of eNOS by unlocking the FMN domain [28].  
Another stimulatory phosphorylation at Ser 617 makes eNOS sensitive to calmodulin 
binding [29]. Phosphorylation at Thr 495, which is mediated by PKC and AMPK, 
weakens the association between calmodulin and eNOS to reduce activity of eNOS [30]. 
Protein phosphatase 2A or phosphatase 1 appears to dephosphorylate Thr 495 and 
enhance binding of calmodulin to eNOS and derepress acitivity of it [31].   
1.2.4 Life Cycle and Signaling Pathways of eNOS. 
Under physiological conditions, p-Ser 1177 of eNOS is phosphorylated in response to 
shear stress, hormones and autocoids such as bradykinin [32]. Insulin and adipokines 
pathways also regulate phosphorylation of Ser1177 [33].   
A large number of kinases, as Akt (protein kinase B), CaM kinaseII 
(calcium/calmodolun-dependent protein kinase ii), and AMPK (AMP-activated protein 
kinase) catalyze phosphorylation at ser 1177 of eNOS. Besides kinases, phosphatases 
such as calcineurin and PP1 play important role in manipulating phosphorylation [34]. 
PKA dependent agonists and basal stimuli such as shear stress activate PKA and induce 
Phosphorylation at Ser 635 [28].VEGF promotes dephosphorylation at Ser116 and 
upregulates activity of eNOS [19]. 
eNOS can also be regulated by numerous eNOS binding proteins including caveolins. 
Caveolins are caveolar membrane proteins that have transmembrane domains and 
reversible C-terminal palmitoylation. In endothelial cells, caveolin-1 and caveolin-2 are 
prevalent [35]. The membrane association and oligomerization of caveolins determines 
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the structure of caveolin. Caveolin also serves as a scaffold for eNOS and other proteins 
to form signaling complexes.   
Although not necessary for localizing eNOS to caveolae, caveolin binds with and inhibits 
the activity of eNOS. Caveolin not only hinders caveolar-targeted receptor signaling but 
also blocks calmodulin binding sites in eNOS [35]. Dissociation from caveolin 
association is a vital early step in activating eNOS. Intracellular calcium, calmodulin and 
shear stress can promote detaching eNOS from cav-1.   
Caveolins are increasingly characterized as contributing to assembly and regulation of 
signaling effectors such as VEGF receptors, PI3K, c-Src kinase, estrogen receptors, etc. 
Many of these effectors are tightly associated with eNOS regulation [36].   
eNOS can also be associated with and regulated by GPCRs. Many GPCRs are linked to 
Gαi or Gαq that stimulate phospholipase C (PLC) that result in mobilization of calcium 
through IP3 mediated signaling events and thereby activate eNOS [37]. These GPCRs 
respond to ligands such as bradykinin, histamine, acetylcholine, S1P, ADP/ATP, and 
thrombin[38]. Subsequent to GPCR stimulation, calcium waves are started initially at 
caveolae, which is confirmed by high resolution microscopy [39].   
Another eNOS activating mechanism besides intracellular calcium mobilization, the 
PI3K/Akt cascade also assists in VEGF-induced eNOS activation. GPCR mediated 
activation of PI3K produces PIP3 (phosphatidylinositol (3,4,5)-trisphosphate) from PIP2 
(phosphatidylinositol (4,5)-bisphosphate). Akt is recruited to plasma membrane by PIP3 
and phosphorylated by phosphoinositide dependent kinase. Phosphorylation of Akt 
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allows it to be stabilized in the active conformation and translocated to the cytoplasm or 
nucleus to phosphorylate its targets, including eNOS [38].   
In addition, GPCR is found to transactivate RTKs and integrins by Gα or Gβy to activate 
PI3K/Akt pathways [40]. Ca2+ waves activate eNOS by helping calmodulin to bind 
eNOS, similarly, after activation, Akt can phosphorylate eNOS at ser 1177, which 
enhances affinity between eNOS and calmodulin and promotes electron transfer and 
upregulates activity of eNOS [30].  
In response to shear stress, Ca2+ activated PI3K/Akt pathway leads to phosphorylation of 
eNOS at Ser 1177 and consequently contributes to maintaining basal vascular tone [28].  
Under quiescent conditions, eNOS is anchored to caveolae by co-translational 
myristoylation and post-translational palmitoylation [41]. Caveolin binds to eNOS to 
confer tonic inhibition [42]. Stimulations can alter post-translational modifications on 
eNOS [28] to increase its activity. Simultaneously, Ca2+ /calmodulin and Hsp90 replace 
caveolin to bind with and activate eNOS [43].   
A slower process of inactivation and internalization of eNOS follows the rapid response 
to agonist stimulation and eNOS activation. eNOS is depalmitoylated to allow 
translocation of eNOS from caveolae to intracellular compartments including peri-
nuclear region, Golgi, mitochondria and cytoskeleton. It has been reported that the 
destination of eNOS translocation differs according to different agonists. For example, 
acetylcholine prefers translocation to Golgi while platelet-activating factor relocalizes 
eNOS to the cytosol [44].   
11 
 
During translocation, eNOS is deactivated through several mechanisms, including 
inhibitory phosphorylation and dephosphorylation of stimulatory loci, uncoupling of 
eNOS from upstream signaling molecules and events, and moving away from the calcium 
wave. Re-nitrosylation also occurs when eNOS is internalized [45].   
eNOS eventually relocalizes to the caveolar membrane by reassociation with caveolin 
and re-nitrosylation. Palmitoylation is involved in eNOS re-targeting to caveolae [46].   
eNOS is responsible for synthesizing most of vascular NO. NO synthesized by eNOS is a 
key gaseous free radical that regulates a large number of cardiovascular and cellular 
events, such as endothelial cell migration, extracellular matrix degradation, proliferation, 
controlling vascular tone, angiogenesis, platelet function, mitogenesis, etc.  
Besides NO, eNOS is also able to produce superoxide O2·−, which reacts with NO to 
form peroxynitrite (ONOO−) with diminished levels of BH4 (eNOS uncoupling). This 
transformation of eNOS into an oxidative stress-promoting enzyme is found in 
cardiovascular diseases [47]. 
1.2.5 eNOS and Shear Stress 
The steady, undisturbed laminar blood flow creates a constant shear stress in straight 
arteries along the EC surface. The exposure of EC to laminar shear stress leads to anti-
atherogenic processes, which prevents lesions in the laminar flow prevalent straight 
arteries. Expression of anti-atherogenic genes including SOD [48], p53 [49], interleukin 
1β-converting enzyme and capase-3 [48] are regulated in response to laminar shear stress. 
One of the best characterized and important shear stress responsive genes is eNOS, which 
catalyzes the production of NO while NO inhibits atherogenesis by repressing SMC 
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proliferation and migration, leukocyte adhesion and platelet aggregation. Shear stress is 
considered to be a critical physiological stimulus to activate eNOS [50]. In cultured ECs, 
1 hour of laminar shear stress elevated eNOS mRNA expression [51]. It was also 
reported that high laminar shear stress increases eNOS mRNA following 2 and 4 hours 
treatment in cannulated and isolated porcine coronary arterioles [48]. It was revealed that 
shear stress results in phosphorylated Ser-1177 on eNOS through the PI3K-Akt pathway 
[28]. Upon increase in flow in intact resistance vessels, NO production was induced by 
short term Ca2+ dependent eNOS translocation and long term Ca2+ + independent 
phosphorylation through PI3K-Akt pathways [52]. Based on in vivo studies, high shear 
stress causes a 3-fold rise of eNOS in the Golgi complex area compared with undisturbed 
or low shear stress. Increased eNOS colocalizing with PECAM-1 is seen in responding to 
high shear and low shear stress compared with oscillatory shear stress [53]. 
As illustrated in Chapter 3, heparin signaling share some factors with laminar shear stress 
response. 
1.3 TMEM184A as A Heparin Receptor 
Heparin has been known to bind vascular cells and regulate their physiology’s 
suppressing proliferation and inflammation. Heparin can bind and be taken up by 
endothelial cells [9], inhibiting their inflammatory responses, and can bind VSMC [13] 
while decreasing MAPK dependent cell proliferation [14].  
Possible explanations have been proposed, including that heparin binding blocking 
proteins are mediating heparin's anti-proliferation and anti-inflammation effects.  
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There is a huge number of heparin binding proteins, including integrin [54], bFGF [55] 
and fibronectin [56].  Some studies report that heparin can be found in nucleus to regulate 
transcription factors [57]. A receptor mediated model is thus suggested for heparin 
response and its transport across the membrane while it is highly charged. A putative 
heparin receptor was found to support this idea. Monoclonal heparin binding blocking 
antibodies were used to immunoprecipitate a membrane protein [58], which was 
identified to be coded by TMEM184A gene4 according to the paper(part of which 
includes some of my work) published in 2016 by the lab [4].  
Transmembrane protein 184A is a multi-pass transmembrane protein as predicted. It is 
not well characterized but a few studies found Sdmg1, its counterpart in male gonads, 
plays a role in membrane trafficking. In SK11 Sertoli cells, TMEM184A colocalizes with 
VAMP containing peri-nuclear and peripheral endosomes [59]. VAMP contributes to 
vesicle fusion in membrane transport [60], [61], [62]. And knocking down TMEM184A 
in sertoli cells results in membrane trafficking defects [59]. In addition, a potential C-
terminal dileucine targeting motif of TMEM184A implies possible endosome/lysosome 
targeting functions. TMEM184A was also suggested to promote interaction between 
intra-lumenal cargo and lipid microdomains or cytosolic membrane trafficking proteins 
[59]. 
In addition, in vascular smooth muscle cells, the putative heparin receptor TMEM184A 
has been found to co-localize with caveolin-1, which is one of the most important eNOS 
associating proteins that regulates activity of eNOS [4].  
1.3.1 Rab11: a GTPase involved in endosomal recycling 
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A large number of recycling membrane components avoid degradation in late endosomes 
and lysosomes by going through the endocytic recycling compartment (ERC). Rab11, 
which is distributed at membrane compartments including TGN (trans-Golgi-network) 
and ERC, is one of the proteins that known to specifically regulate transport from ERC to 
both the cell surface and TGN [63]. Transport from ERC can be blocked by deficiency in 
Rab11[63].  
Integrin is one of the transmembrane proteins that can be trafficked from plasma 
membrane into endosomal compartments and recycled back to cell surface. Such 
trafficking and recycling regulated integrin's functions including controlling cell 
migration and proliferation. Various Rab GTPases regulate trafficking of integrin. Some 
integrins can be endocytosed through Rab21 mediated clathrin independent process [64]. 
Subsequently, Rab4 mediates the fast recycling from early endosomes back to plasma 
membrane while Rab11 mediates the slow recycling through the perinuclear recycling 
compartment [65]. 
The RAB11 family of GTPases is found in post-Golgi membranes, perinuclear recylcing 
endosomes. It is well known to regulate endocytosed cargos. It is also revealed to 
regulate vesicle exocytosis at plasma membrane [66]. Rab11 is commonly used as a 
marker for Perinuclear recycling compartment, which located in juxtanuclear region and 
needs Rab11 for its function and morphology. Many endocytosed recptors such as 
integrins are delivered here before recycling back to plasma membrane [67]. Rab11 is 
involved in building motor protein complexes [68] and transporting of recycling 
endosomes [69]. Based on the fact that TMEM184A co-localizes with eNOS at 
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perinuclear regions and it is highly suspected in membrane trafficking, it is reasonable to 
see if TMEM184A co-localize with Rab11 or work together in some way. 
Activities and distributions of integrin can be regulated by its internalization and 
recycling. For example, a Rab11 dependent pathway can increase recycling of α5β1 
integrin and triggers activation of ROCK and inactivation of cofilin [67]. As mentioned 
above, TMEM184A might interact with integrin and they might associate with each other 
in caveolae. If TMEM184A participates in recycling, it is possible that it regulates 
recycling of integrin or conversely. 
1.3.2 Background on Integrin Mechanotransduction 
Integrins are a family of cell surface glycoproteins composed of 18 alpha and 8 beta 
subunits that can be assembled to 24 combinations and 13 out of 24 are found in VSMCs 
(α1β1, α2β1, α3β1, α4β1, α5β1, α6β1, α7β1, α8β1, α9β1, αvβ1, αvβ3, αvβ5, αnd α6βv) 
[70]. Integrin binding to fibronectin promotes significant mitogenic responses in VSMCs 
while RGD peptides and antibodies to integrin αvβ3 or αvβ5 but not β1 abolish the 
mechanical strain induced mitogenic response in VSMCs [71]. These data show 
mechanical strain induced myogenic response requires specific integrin subunits in 
VSMCs.  
The extracellular domain of the subunits binds to ECM proteins while the cytoplasmic 
domains associate with cytoskeletal proteins such as actin and signaling proteins to 
trigger cytoskeletal organization and signal transduction. The different integrin 
expression patterns determine the specific type of ECM proteins to which the cell can 
bind [72]. Integrin recognizes and binds to RGD motifs, which are present in many ECM 
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proteins including laminin and thrombospondin [73]. The specificity of integrin in 
binding to various matrix proteins is dictated by amino acids surrounding the RGD 
sequence [73].  
Integrin mediates rapid and spatially bidirectional signaling between ECM and the 
intracellular environment. Integrins are clustered when bound by ligands and the 
clustering allows enhanced activity of integrin receptors [74].  
Existing studies show that many integrin induced signaling pathways are also activated 
by shear stress. Integrin activation is mainly achieved by using antibodies against 
integrins or attaching cells to ECM proteins [75]. Such evidence supports that integrins 
are mediating mechanotransduction. Integrins are reported to be activated by shear stress. 
Shear stress leads to conformational change of integrin αvβ3 in BAOECs and results in 
higher affinity between integrin and its ligands confirmed by an integrin ligand mimetic 
Fab fragment [76]. Many shear stress activiated kinases as ERK and FAK are under 
control of integrins. FAK and Shc are known to manipulate MAPK activation by shear 
stress. When stimulated by growth factors, integrins co-localize with growth factor 
receptors and their associated signalling proteins as FAK, Src and cytoskeletal molecules 
at focal adhesion sites and regulate the downstream effectors such as AKT, ERK and 
JNK [77]. ERK is activated through paxillin, p130, CAS, Crk, C3G, Rap-1, and Raf 
which is dependent on intergin induced FAK/c-Src pathway. 
1.3.3 Integrin and Galectin-3 
The β1 integrin is implicated to be a binding protein for gal-3 (galectin-3 [78], a pro-
angiogenic carbohydrate-binding protein and a tumor associated lectin. Gal-3 is found to 
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mediate VEGF and bFGF dependent angiogenic response [79] while up to 30 times as 
much of gal-3 can be found in the circulation of cancer patients [80]. Blocking the major 
gal-3 ligand integrin αvβ3 significantly hindered the galectin-3–induced angiogenesis 
while gal-3 elevated the clustering of integrin αvβ3 and activated FAK (focal adhesion 
kinase) [79]. 
Other membrane proteins are potential to be involved in TMEM184A signaling 
pathways. Gal-3, as a member of lectin and possess a conserved sequence within the 
CRD (carbohydrate recognition domain) that bind to B-galactoside structures. 
Chemically modified heparin derivatives inhibited gal-3-ligand binding and gal-3 
dependent cancer cell-endothelial adhesion and angiogenesis [81]. Gal-3 has also been 
reported to promote cell migration through MAPK/ERK1/2 pathway [82].  
1.3.4 VE-cadherin 
VE-cadherin is implicated to be part of the mechanosensing protein complex on 
endothelial cells in sensing blood shear stress [83]. Onset of shear stress down-regulates 
tension across VE-cadherin and total cell-cell junctional tension [84]. Local cytoskeleton 
remodeling including actin and vinculin recruitment can be triggered by VE-cadherin 
mediated mechanotransduction [85]. There is known cross talk between the two 
transmembrane adhesion receptors, integrin and VE-cadherin, which share many 
downstream effectors and cytoskeletal proteins. There are lateral associations between 
integrin and VE-cadherin [86]. Both of the two receptors are able to increase expression 
of cyclin D1 through Rac to enhance cell proliferation [87]. 
1.3.5 Heparin Signaling and Mechanotransduction 
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Heparin and laminar shear stress have some similar anti-proliferative and anti-
inflammatory responses. As heparin, laminar shear stress can also suppress proliferation 
of endothelial cells and VSMCs [88]. Chronic shear exposure decreases ERK activation 
whereas the Akt response is increased [89]. As mentioned earlier, heparin can down-
regulate ERK's activity. And Akt might be upregulated by heparin since heparin 
treatment causes increase in cGMP3, which responds to Akt-eNOS signaling [21].  
In addition, chronic laminar shear increases the number of caveolae by 45-48% above 
control and caveolin-1 translocates from Golgi to the luminal plasma membrane. Such 
regulation of caveolae might play significant role in endothelial mechanosensing [89]. 
TMEM184A has also been suggested to accelerate intra-lumenal cargo interaction with 
cytosolic membrane trafficking proteins or lipid microdomains [90]. The re-distribution 
of caveolin-1 might result in a change in activity and localization of eNOS, which is 
predicted to play a role in heparin signaling.  
Shear stress itself can modulate glycocalyx and results in modification of membrane 
receptors. Shear stress can redistribute the glycocalyx on endothelial cells [91]. And 
heparan sulfate proteoglycan is required for shear stress induced NO production [23].  
This evidence implies that heparin signaling might be linked with mechanosensing events 
of the shear stress response and TMEM184A might contribute to or be related to 
mechanotransduction processes by interacting with canonical players of 
mechanotransduction.  
Among the members involved in mechanosensing, integrins might interact with heparin 
signaling and TMEM184A. As cell surface receptors, integrins mediate cell-cell and cell-
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matrix adhesion. Integrins and the adhesions they form are critical in transducing 
mechanical signals through the cell membrane. 
Many shear stress-activated kinases, including ERK and FAK, are under the regulation of 
integrin. ERK, which is known to be affected by heparin treatment, can be activated 
through an integrin dependent FAK/c-Src pathway. Shear stress is able to activate 
integrin and induce the downstream signaling through rapid activation of tyrosine 
kinases, including FAK in focal adhesions [49], which consequently activate ERK [80].  
There have also been reports about links between heparin and integrin. The ectodomain 
of α5β1 integrin binds to heparin with high affinity (KD = 15.5 nM) [93]. Heparin also 
binds to αvβ3 integrin [93]. It is hypothesized that the direct binding between 
heparin/heparan sulfate and integrins is required for the localization of endostatin in 
endothelial cell lipid rafts [94]. Endostatin is a C-terminal fragment derived from type 
XVIII collagen. It is an angiogenesis inhibitor and found to block growth factors such as 
VEGF mediating pro-angiogenic action [95].  
The stimulation of HSPG synthesis and sulfation pattern modification are found to be 
mediated by interaction between heparin and integrin while RGD peptides block such 
effects [96]. And this up-regulation is associated with phosphorylation of focal adhesion 
proteins, MAPK pathways, and NO pathways [96].  
Based on this evidence, integrin might be involved in heparin signaling through a 
mechanosensing based mechanism such as cross activation of RTKs and their 
downstream signaling effectors or possibly through its binding with heparin to control 
localization of endostatin to suppress proliferation.  
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1.4: Figures 
1.1 eNOS’s acitvity is also regulated by phosphorylation 
 
 
  
 
 
The figure shows the known eNOS is regulated by heparin. The figure is borrowed from 
a paper referenced [24]. 
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Chapter 2: TMEM184A plays a role in heparin binding and 
uptake: Confirmation of the heparin receptor identity 
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2.1: Introduction 
Heparin has been known to bind to and be internalized by vascular cells [9] and regulate 
their physiology as suppressing proliferation and inflammation [14]. Heparin can bind 
and be taken up by endothelial cells [9], inhibiting their inflammatory responses, and can 
bind VSMC [13] while decreasing MAPK dependent cell proliferation [14]. 
Possible explanations have been proposed, including that heparin binding blocking 
proteins are mediating heparin's anti-proliferation and anti-inflammation effects. 
There is a huge number of heparin binding proteins, including integrin [54], bFGF [55] 
and fibronectin [54]. Some studies report that heparin can be found in the nucleus to 
regulate transcription factors [57]. A receptor mediated model was thus suggested by 
previous members of our lab and others to account for the heparin response and its 
transport across the membrane considering it is highly charged [2]. 
Much of the work described in this chapter was published in The Journal Of Biological 
Chemistry [4] and Journal of Visualized Experiments [97]. Earlier work from our lab also 
determined that monoclonal antibodies, which block heparin binding to endothelial cells 
[17], lead to similar heparin effects in vascular endothelial cells [58] and in vascular 
smooth muscle cells [17]. 
A former member of our lab, Raymond Pugh Ph.D., used the heparin binding blocking 
antibodies to isolate and purify the heparin receptor from BAOECs [4].  
Raymond obtained protein sequence data by using MALDI-TOF(Matrix-Assisted Laser 
Desorption/Ionization – Time of Flight) Mass Spectrometry.through collaboration with 
previous member of our lab, Walter Patton Ph.D. Cleavage products of the peptides by 
carboxypeptidase Y were analyzed by MALDI-TOF to determine sequencing of the 
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peptide fragments [98]. Then bioinfomatic searches was used to analyze similarities to 
known proteins in the database. Identified by MALDI-TOF Mass Spectrometry, the 
protein product was revealed to be an uncharacterized membrane protein, coded by 
TMEM184A gene [4]. 
Subsequent research from the lab suggests that TMEM184A is involved in mediating the 
heparin responses in VSMCs (reported in Chapter 3) as it is required for heparin induced 
attenuation of PDGF-activated pElk-1 and synthesis of DUSP1 which regulates ERK's 
activity. To support the hypothesis that TMEM184A is interacting with heparin to trigger 
downstream signaling events, we determined to examine if TMEM184A binds with 
heparin and participates in heparin uptake. 
We used Monoclonal heparin binding blocking antibodies to precipitate samples from 
BAOECs and A7r5s. The samples were recognized by commercial TMEM184A antibody 
to examine if the heparin binding blocking antibodies which mimic heparin is binding 
with TMEM184A.  
 
2.2: Methods 
 
2.2.1 Materials 
Anti-TMEM184A (catalog no. sc292006, N-terminal domain, NTD, rabbit; catalog no. 
sc163460, internal domain, INT, goat) were from Santa Cruz Biotechnology 
(La Jolla, CA). Anti-TMEM184A (C-terminal domain, CTD, rabbit) was obtained from 
ProSci Inc. (Poway, CA). Secondary antibodies with fluorescent tags or Biotin-labeled 
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(donkey or bovine for goat primary antibodies, minimal cross-reactivity) were obtained 
from Jackson ImmunoResearch Laboratories, Inc. (West 
Grove, PA). Extra-avidin-alkaline phosphatase TM, 5-bromo-4-chloro-3-indolyl 
phosphate, and nitro blue tetrazolium were obtained from Sigma. 
 
 
2.2.2: Cell Culture 
 
A7r5 rat smooth muscle cells were obtained from the ATCC (Manassas, VA). Bovine 
aortic endothelial cells (BAOECs), A7r5s were cultured, harvested and analyzed as 
described previously [4]. 
 
2.2.3: Western Blotting 
 
2X sample buffer was added to cell sample buffer and boiled at 100oC for 5 min. The 
protein samples were separated by SDS-PAGE. The blots were developed with nitro blue 
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate and alkaline phosphatase system as 
described in our earlier paper [4].  
 
2.2.4: Co-Immunoprecipitation 
 
Confluent 150-mm dishes of BAOECs or A7r5 cells were washed 3 times with ice-cold 
PBS. 1ml ice-cold RIPAs buffer supplemented with two protease inhibitor cocktails 
(Sigma, catalog nos. P8340 and P2714) were added after PBS was drained. The cells 
were then agitated on rocker for 30 min at 4oC. After incubation, the cells were scraped 
off the dishes and transferred to a cold microcentrifuge tube and centrifuged for 10 min at 
10,000×g at 4oC. The supernatant was incubated at 4oC on a rocker overnight with 
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antibody targeting eNOS. Following that, 75 μl of equilibrated EZview red protein G 
affinity gel beads (Sigma) were added and incubated on a rocker at 4oC overnight. The 
beads were washed 3 times with the RIPA buffer with the protease inhibitors added. The 
beads in 200μl sample buffer were then boiled for 5 min and the supernatant was 
collected for running western blotting. 
 
2.2.5: TMEM184A Knockdown 
 
Stable transfection of A7r5 cells was accomplished by transfecting the TMEM184A 
shRNA construct which allows for puromycin selection and GFP expression as described 
in our earlier paper [4]. After electroporation, the cells were plated onto 100-mm dishes 
for 48 hours normal growth. Then minimum Eagle’s medium containing 3μg/ml 
puromycin was changed every 2 days for 4 times. Surviving colonies were transferred to 
a 35-mm dish for 7 more days growth in puromycin selection medium. Cells were later 
examined for GFP and TMEM184A expression.  
 
2.2.6: Indirect Immunofluorescence 
 
 Cells were fixed with ice-cold methanol (MeOH) for 5 min at 4oC, washed three times in 
PBS. The coverslips were incubated with primary antibodies at 4oC overnight. Following 
this incubation, coverslips were rinsed with PBS and incubated with proper secondary 
antibodies with lowest cross-reactivity conjugated to desired fluorofours for 45 min at 37 
°C. Secondary antibody-only controls were carried out to exclude nonspecific staining. 
Cells were imaged using a Zeiss LSM 510 Meta microscope with a ×40 oil immersion 
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lens at room temperature. Staining for Erk and Elk-1 upon eNOS KD were also imaged 
using Nikon eclipse TE 2000-U fluorescence microscope (Nikon, Tokyo Japan) and the 
fluorescence intensity was relativized. Fluorescence intensity of the cell was determined 
using Image J. Statistical significance was determined by One-way ANOVA (ANalysis 
Of VAriance) with post-hoc Tukey HSD (Honestly Significant Difference). 
 
2.2.7: GFP-TMEM184A Expression.  
 
Vascular cells were trypsinized and pelleted from 100 mm dishes. Cell pellets were 
resuspended in 1ml of HeBS(Hepes-buffered saline) electroporation buffer. GFP-tagged 
TMEM184A construct was added to the cells at 20μg/ml. 1ml of the solution was placed 
in an electroporation cuvette. The cells in the cuvette were electroporated in 
electroporation chamber by 170V and then seeded into 30 mm dish. 
 
2.2.8: Rhodamine-Heparin Binding and Uptake. 
 
GFP-TMEM184A expressing A7r5s were incubated with 100μg/ml rhodamine heparin 
in dark at 37°C for 10 mins and then fixed by 4% PFA. 
 
2.2.9: Live Cell Imaging 
GFP-TMEM184A expressing A7r5s were grown in MatTek (Ashland, MA) 35-mm 
dishes for at least 24 hours before confocal microscope observation. After the cells were 
in focus, rhodamine heparin was added into cell culture. 
 
2.3: Results 
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2.3.1: TMEM184A co-immunoprecipitated with anti-heparin receptor monoclonal 
antibodies  
 
Monoclonal heparin binding blocking antibodies were used to precipitate samples from 
BAOECs and A7r5s. The samples will be recognized by commercial TMEM184A 
antibody to examine if the heparin binding blocking antibodies which mimic heparin is 
binding with TMEM184A. 
Co-IP from BAOECs and A7r5s by the monoclonal heparin binding blocking antibodies 
and commercial antibodies against N-terminal of TMEM184A resulted in identical 
western blot staining with antibodies against internal region of TMEM184A (Figure 2.1). 
 
2.3.2: TMEM184A is necessary for rhodamine-heparin uptake in A7r5s 
Both wild-type A7r5 cells and TMEM184A stable knockdown A7r5s were transfected 
with the GFP-TMEM184A construct or not and incubated with rhodamine-heparin. 
Heparin uptake was analyzed in these types of cells. TMEM184A stable knockdown 
A7r5s has significantly lower rhodamine-heparin uptake than normal A7r5s. Transfection 
of GFP-TMEM184A into the stable knockdown cells recovers the uptake. Transfection of 
GFP-TMEM184A into the normal A7r5s results in elevated rhodamine heparin uptake 
(Figure 2.2AB). 
 
2.3.3: TMEM184A co-translocate with Internalized heparin  
 
A7r5s transfected with GFP-TEM184A were incubated with rhodamine heparin and 
observed immediately under confocal microscope by live imaging to investigate whether 
TMEM184A is participating in heparin uptake. The internalized rhodamine heparin was 
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enclosed by GFP-TMEM184A and these two proteins co-translocate as a vesicle (Figure 
2.2 C). 
 
2.3.4: TMEM184A stable knockdown significantly lowered the level of TMEM184A  
In A7r5 cells 
 
The level of TMEM184A in TMEM184A stable knockdown cells were determined by 
examining the level of TMEM184A stained by antibody against N-terminus and GFP-
shRNA expression. The result shows that TMEM184A was significantly reduced in the 
stable knockdown cells (Figure 2.3). 
 
2.3.5: TMEM184A associates with Rab11 
 
Anti TMEM184 antibodies were used to precipitate samples from BAOECs and A7r5s. 
The samples will be recognized by anti-Rab11 antibody. The results indicate that 
TMEM184A directly or indirectly associates with Rab11 (Figure 2.4). 
 
2.4: Discussion 
 
The results presented here provide evidence that heparin bind with and endocytosed with 
TMEM184A. By knocking down TMEM184A, the endocytosis of heparin is abolished. 
After re-expressing TMEM184A, the uptake of heparin is restored. The stable 
knockdown of TMEM184A allows for functional study of its role in heparin signaling. 
As illustrated in Chapter 3, TMEM184A knockdown abolished heparin’s effects 
including regulation of eNOS activation. Data presented in this chapter and chapter 3 
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supports the fact that TMEM184A is the receptor of heparin and mediates heparin 
signaling including p-ERK, p-ELK down-regulation.  
There are not many researches of TMEM184A published. TMEM184A’s function is not 
known well. But some studies suggest TMEM184A might be involved in membrane 
trafficking. TMEM184A possesses a C-terminal potential dileucine targeting motif 
known for mediating endosome/lysosome targeting [59]. In SK11 Sertoli cells, knocking 
down TMEM184A, which localized to endosomes knock down resulted in membrane 
trafficking defects [59]. TMEM184A was also found to co-localize with various VAMP 
containing endosomes. TMEM184A was also proved to co-localize with cav-1 in 
BAOECs based on previous data of the lab [4].  Results in Chapter 3 showed that 
TMEM184A co-localize with eNOS at endosomal recycling compartment (Figure 3.3). 
And the distribution pattern that amount of TMEM184A accumulated at perinuclear 
region outweigh those at plasma membrane region and cytoplasm suggest that 
TMEM184A might undergo higher rates of internalization rather than recycling back to 
plasm membrane. Thus, it makes sense to explore the role of TMEM184A in membrane 
trafficking. 
Results here show that TMEM184 associates with Rab11 (Figure 2.4). The RAB11 
family of GTPases is found in post-Golgi membranes, perinuclear recylcing endosomes. 
It is well known in regulating endocytosed cargos. It has also revealed to regulate vesicle 
exocytosis at plasma membrane [66]. Rab11 is commonly used as a marker for 
Perinuclear recycling compartment, which located in juxtanuclear region and need Rab11 
for its function and morphology. Many endocytosed recptors such as integrins are 
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delivered here before recycling back to plasma membrane [67]. Rab11 is involved in 
building motor protein complexes [68] and transporting of recycling endosomes [68]. 
Based on the fact that TMEM184A co-localizes with eNOS at perinuclear regions and it 
is highly suspected in membrane trafficking, it is reasonable to see if TMEM184A work 
together with Rab11. It is not clear if the TMEM184A at perinuclear region is under 
recycling between plasma membrane and ERC or is just synthesized and transported to 
Golgi. In order to answer this question, sub-cellular distribution GFP-TMEM184A can be 
monitored either by fixation at different time points or live cell imaging while blocking 
new protein synthesis with cycloheximide after 48hrs of expression. If TMEM184A is 
not involved in recycling, there should be a decrease of TMEM184A at perinuclear 
region after a period of time while significant level still can be seen on plasma 
membrane. Alternatively, the expressed TMEM184A can be tracked to see if those 
delivered to plasma membrane after expression will be internalized and go back to 
membrane again. If TMEM184A is proved to be part of the recycling process, further 
experiments are to be done to see if adding heparin is affecting the recycling process. 
Considering that fact that TMEM184A associates with integrin (Chapter 3). It is possible 
that TMEM184A assist in integrin recycling. Activities and distributions of integrin can 
be regulated by its internalization and recycling. For example, a Rab11 dependent 
pathway can increase recycling of α5β1 integrin and triggers activation of ROCK and 
inactivation of cofilin [67]. As mentioned above, TMEM184A might interact with 
integrin and they might associate with each other in caveolae. If TMEM184A participate 
in recycling, it is possible that it regulates recycling of integrin or conversely. 
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2.5: Figures 
2.1 Immunoprecipitation of the heparin receptor detects TMEM184A. 
 
A                                       B 
 
 
 
 
 
 
 
 
 
 
 
 
A, BAOECs were harvested for immunoprecipitation (IP) as 
described under “Experimental Procedures.” A and B, similar BAOEC lysates (A) 
and A7r5 lysates (B) were divided into identical fractions and incubated with 
12B1, commercial NTD TMEM antibody, or beads alone (B). A whole cell (WC) 
sample was also used in A. Blots were developed using INT TMEM184A antibody 
and are representative of three repeats. Bands near the bottom of the 
blots are also seen with secondary antibodies only. All blots were developed 
and converted to grayscale for post-hoc analysis as described under “Experimental 
Procedures.” 
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2.2 GFP-taggedTMEM184Acolocalizes with rhodamine-heparin 
A 
 
 
B                                        C 
                                             
 
  
A, A7r5 cells and stable knockdowns for TMEM184A were treated with 100μg/ml 
rhodamine-heparin for 10 min and fixed with 4% PFA. Images are representative of 
duplicates from two separate experiments. Scale bars=10 μm. B, A7r5 cells and stable 
knockdowns for TMEM184A (KD) were either transfected with the GFP-TMEM184A 
construct or not transfected and treated as in B. At least 50 cells/condition (in each of 
three experiments) were analyzed for heparin uptake. **, p<0.0001. C, GFP-
TMEM184A-transfected A7r5 cells were incubated with 200μg/ml rhodamine-heparin, 
and cells were imaged immediately without fixing. Time-lapse confocal microscopy 
initiated at about 4 min after heparin addition identified colocalization of rhodamine-
heparin (white vertical line) with a cluster of the GFP-TMEM 184A construct (scan zoom, 
6.9; objective, X63/1.4 oil differential interference contrast). The reference white bar 
points to the initial location and is a reference for concurrent movement of both labels. 
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2.3 TMEM184A stable knockdown significantly lowered the level of TMEM184A  
In A7r5 cells 
 
 
 
GFP-shRNA of TMEM184A       N-term of TMEM184A 
 
 
A7r5 stable knockdowns for TMEM184A were fixed with 4% PFA for 15min and 
stained with antibodies against N-term of TMEM184A and imaged under epifluorescence 
microscope. 
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2.4 Immunoprecipitation of TMEM184A detects Rab11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunoprecipitation by TMEM184 NTD antibodies in A7r5s (no treatment) show 
association between TMEM184A and Rab11. 
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Chapter 3: Heparin treatment regulates eNOS while eNOS 
plays a role in heparin signaling 
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3.1: Introduction 
Heparin is known to bind vascular cells and regulate their physiology. For example, 
treatment of vascular cells with heparin can suppress proliferation and inflammation [4]. 
Heparin can bind to and be taken up by endothelial cells [9], inhibiting their 
inflammatory responses via decreasing NF-κB and stress kinases pathways [99], and can 
bind VSMC [13] while decreasing MAPK dependent cell proliferation [16]. Protein 
kinase G signaling is at least partially responsible for heparin's anti-proliferative effects 
on VSMCs [18]. A receptor-mediated model is hence suggested for the heparin responses 
and heparin transport across the membrane. A heparin receptor, TMEM184A, was 
recently identified and supports this idea [4]. 
Numerous studies provide evidence supporting the hypothesis that heparin and its 
derivatives can regulate eNOS, an important producer of NO, which leads to the 
activation of PKG. Both heparin and its non-anti-coagulant derivative, N-acetyl heparin, 
dose-dependently increase eNOS activity by promoting citrulline and nitric oxide 
metabolite formation in BAOECs [19]. In vivo experiments suggest that heparin can 
increase NOS activity and cGMP levels in lung at both three days and three weeks [19].  
In cell lines including RAOSMCs and BAOECs, the heparin receptor TMEM184A has 
been found to co-localize with caveolin-1 [4], which is one of the most important eNOS 
associating proteins that regulates activity of eNOS [100]. Although not necessary for 
localizing eNOS to caveolae, caveolin binds with and inhibits the activity of eNOS 
[101]). Caveolin not only hinders caveolar-targeted receptor signaling but also blocks 
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calmodulin binding sites in eNOS [44]. Dissociation from caveolin is a vital early step in 
activating eNOS. 
A principle post-translational regulation of eNOS activity is through multisite 
phosphorylation, and dephosphorylation at key serine and threonine residues in eNOS. 
Stimulatory phosphorylation loci include Ser 1177 (human, Ser1179 in bovine), Ser 617, 
and Ser 635, while inhibitory sites are Thr 495 and Ser 116 [102]. Various kinases such 
as Akt, CaM kinase and AMPK, shear stress, hormones and other stimuli can cause 
phosphorylation at Ser1177 of eNOS. It was revealed that shear stress, which shares 
similar anti-proliferative and anti-inflammatory responses with heparin in vascular cells 
[88] resulted in phosphorylated Ser-1177 on eNOS through the PI3K-Akt pathway [89]. 
An increase in flow in intact resistance vessels induces NO production by short term Ca2+ 
dependent eNOS translocation and long term Ca2+ independent phosphorylation through 
PI3K-Akt pathways [52]. PP2A and PP1 are phosphatases found to dephosphorylate Thr 
495 and Ser p1177 [101] of eNOS. Heparin is reported to inhibit PP1 [103] Hence it is 
possible that heparin treatment inhibits PP1 or PP2A, and consequently upregulates level 
of Ser p1177 eNOS. 
Heparin's anti-inflammatory and anti-proliferation signaling pathway has overlap with 
laminar shear stress response. Laminar shear stress and heparin can both reduce SMC 
proliferation and activity ERK1/2. And they can modulate the alignment and morphology 
in a similar way. Thus, heparin with its receptor TMEM184A may play roles in 
mechanotransduction processes by interacting with some classic members of 
mechanotransduction signaling system. We anticipated integrin which is vital in the 
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mechanosensing complex to be one of those members. Integrin is an upstream factor of 
eNOS and Erk1/2, which are regulated in response to heparin treatment.  
There are facts indicating integrin might be involved. First integrin is vital in the 
mechanosensing complex and secondly it is an upstream factor of Akt, eNOS and 
ERK1/2 (which are important or potentially important in heparin signaling). In addition, 
integrins are present in both ECs and SMCs (heparin effect exists in both ECs and 
SMCs). There are also published results showing that up-regulation of HSPG synthesis 
induced by heparin in endothelial cells is dependent on the interaction of heparin with 
integrin while RGD peptide abolishes the effect [104]. This up-regulation is also 
associated with the phosphorylation of focal adhesion proteins and Ras/Raf/MEK/ERK 
MAP and Ca2+ /NO pathways which are downstream signaling factors of integrins 
confirmed by using inhibitors of Ras, MEK, NOS. Besides the relevance in signaling 
events between intergrin and TMEM184A, there are also many reports for interactions 
between integrin and caveolin. For example, β1 Integrin/caveolin-1 mechano-signaling 
complex respond to shear stress and lead to RhoA and actin Remodeling [105]. β1 
integrin endocytosis is dependent on caveolin-1 [106]. There is also evidence suggesting 
that integrin controls localization of CEMMs [107] at the plasma membrane to regulate 
cellular processes [108]. Given the fact that TMEM184A co-localizes with caveolin-1 
[4], it is possible that TMEM184A also interacts with integrin in caveolae or lipid rafts. 
Thus, the relationship between integrin, TMEM184A and heparin becomes good to study.  
Interaction between heparin and integrin has been reported to be necessary in various 
signaling events. Heparin is known to bind to αvβ3 integrin [93] and α5β1 integrin [94]. 
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Antibodies to integrin αvβ3 or αvβ5 but not β1 abolish the mechanical strain induced 
mitogenic response in VSMCs [71]. Integrin αvβ3 is also a major galectin-3–binding 
protein while antibodies that blocks αvβ3 integrin's function significantly inhibited the 
galectin-3–induced angiogenesis. In SMCs, the occupancy of the heparin binding domain 
of αvβ3 ligand is necessary for proliferative effects of IGF-1 including phosphorylation 
of ERK [109]. These facts make αvβ3 integrin an interesting protein to investigate with 
regard to possible involvement in TMEM184A and heparin signaling.  
It has been reported that association between some types of integrin and gal-3 induced 
angiogenic response while gal-3 promoted clustering of the integrins and activated FAK. 
And MAPK/ERK1/2 pathway is also mediating gal-3 signaling events.  
 
In this study, we confirmed that heparin effects on Erk/Elk required eNOS's activity. 
Interaction between heparin and TMEM184A elicited activation of eNOS by increasing 
its Ser 1177 phosphorylation.   
 
3.2: Methods 
3.2.1: Cell Culture 
A7r5 rat smooth muscle cells were obtained from the ATCC (Manassas, VA). Bovine 
aortic endothelial cells (BAOECs), TMEM184A knockdown A7r5s were cultured, 
harvested and analyzed as described previously [4]. 
 
3.2.2: Western Blotting 
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2X sample buffer was added to cell sample buffer and boiled at 100oC for 5 min. The 
protein samples were separated by SDS-PAGE. The blots were developed with nitro blue 
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate and alkaline phosphatase system as 
described in our earlier paper [4]. The blots in shown Figs. 5 employed secondary 
antibodies 
conjugated to fluorophore (diluted 1:5000). And the bands were visualized by 
fluorescence detection using the Bio-Rad ChemiDoc MP system (catalog no. 170-8280). 
 
3.2.3: Co-Immunoprecipitation 
Confluent 150-mm dishes of BAOECs or A7r5 cells were washed 3 times with ice-cold 
PBS by three times. 1ml ice-cold RIPAs buffer supplemented with two protease inhibitor 
cocktails (Sigma, catalog nos. P8340 and P2714) as added after PBS was drained. The 
cells were then agitated on a rocker for 30 min at 4oC. After incubation, the cells were 
scraped off the dishes and transferred to a cold microcentrifuge tube and centrifuged for 
10 min at 10,000×g at 4oC. The supernatant was incubated at 4oC on a rocker overnight 
with antibody targeting eNOS identified here. Following that, 75 μl of equilibrated 
EZview red protein G affinity gel beads (Sigma) were added and incubated on a rocker at 
4oC overnight. The beads were washed 3 times with the RIPAs buffer with the protease 
inhibitors added by three times. The beads were then boiled in SDS PAGE sample buffer 
for 5 min and the supernatant was collected for running western blotting. 
 
3.2.4: eNOS Knockdown    
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A7r5 cells were trypsinized, rinsed with PBS, suspended in HEPES-buffered saline, 
electroporated with 20 μg/ml of eNOS siRNA, control siRNA, or only electroporated 
with the preset Hela protocol, plated and grown on glass cover slips. The cells were 
treated and harvested after 48 hours post electroporation.  
 
3.2.5: TMEM184A Knockdown 
Stable transfection of A7r5 cells was accomplished by transfecting the TMEM184A 
shRNA construct as described in chapter 2. 
 
3.2.6: Indirect Immunofluorescence 
 Cells were fixed with ice-cold methanol (MeOH) for 5 min at 4oC, washed three times in 
PBS. The coverslips were incubated with primary antibodies against specific primary 
antibodies at 4oC overnight. Following this incubation, coverslips were rinsed with PBS 
and incubated with proper secondary antibodies with lowest cross-reactivity conjugated 
to desired fluorofuors for 45 min at 37 °C. Secondary antibody-only controls were carried 
out to exclude nonspecific staining. Cells were imaged using a Zeiss LSM 510 Meta or 
Zeiss LSM 880 microscope with a ×40 oil immersion lens at room temperature. Staining 
for Erk and Elk-1 upon eNOS KD were also imaged using Nikon eclipse TE 2000-U 
fluorescence microscope (Nikon, Tokyo Japan) and the fluorescent intensity was 
relativized. Fluorescent intensity of the cell was determined using Image J. Statistical 
significance was determined by One-way ANOVA (ANalysis Of VAriance) with post-
hoc Tukey HSD (Honestly Significant Difference). 
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3.2.7 Drug Treatment 
Cells were treated with 50 μmol/L RGD for 30 min, KN-93 0.001 μmol/ml 30 min, GSK 
2193874 15 μM 30 min, RN1734 10 µM 30 min, or EGTA 5 mmol/L 30 min. Cells were 
processed for IF and analyzed as above. 
 
 
3.3: Results 
3.3.1: Knockdown of eNOS Abolishes Heparin Responses in VSMCs 
In order to determine whether eNOS is necessary in heparin effects in VSMCs, A7r5 
cells and BAOECs were transfected with small interfering RNA (siRNA) for eNOS to 
down-regulate its expression. eNOS levels are significantly reduced in eNOS knocked 
down cells 48h post transfection compared to control siRNA transfected cells.  
These results verified that eNOS play an important role in heparin response mediated by 
MAPK pathway in VSMCs (Figure 3.1). 
 
3.3.2: Heparin Increases P-Ser 1177 eNOS in VSMCS Dependently of TMEM184A 
To investigate how eNOS is involved in the heparin signaling pathway, we examined 
whether heparin regulates phosphorylation of eNOS at ser 1177, a pivotal stimulatory 
post-translation modification site and whether TMEM184A mediates such potential 
regulation.  
A7r5s and stable knockdowns for TMEM184A were incubated with or without heparin at 
37°C and then fixed at 3, 13 and 23 minutes, and subsequently stained with Phospho-
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eNOS (Ser1177) Antibody. The results show that heparin treatment caused increased 
eNOS phosphorylation at Ser1177 as early as 3 min and retained at 13 min in A7r5s but 
not in stable TMEM184 stable knockdown A7r5 cells (Figure 3.2). The level of p-Ser 
1177 eNOS reached a peak after the A7r5 cells were incubated with heparin for 3 min 
among the times as in Fig 2. After 23 min of heparin treatment, p-Ser1177 eNOS level 
was dropped approaching original basal level in A7r5 cells (Figure 3.2). Whereas in 
TMEM184A stable knockdown A7r5 cells, heparin did not induce elevation of p-Ser1177 
eNOS after 3 min or 13 min treatment but slightly down-regulated p-Ser1177 eNOS after 
23 min incubation (Figure 3.2).   
 
3.3.3: eNOS Co-localizes with TMEM184A in Vascular Cells 
TMEM184A has been implicated in membrane trafficking [90]  and found to co-localize 
with caveolin-1 [4], suggesting that TMEM184A might play a role in regulation of 
activity or translocation of eNOS by interacting with eNOS. To confirm that 
TMEM184A is an eNOS binding partner, vascular cell proteins immunoprecipitated with 
eNOS antibodies and were analyzed by TMEM184A NTD antibodies. TMEM184A 
staining was observed by TMEM184A NTD antibodies instead of affinity beads alone 
(Figure 3.3A). Through immunofluorescent assays in which we co-stained the cells for 
TMEM184A and p-Ser 1177 eNOS with or without heparin treatment, it can be observed 
that an elevated amount of p-Ser 1177 eNOS resided together with TMEM184A at focal 
adhesion sites and on cell membrane after incubation with heparin for 3 min compared to 
that under quiescent status. After 13 min, the level of p-Ser 1177 eNOS and TMEM184A 
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on cell membrane was reduced but increased at peri-nuclear region. After 30 min, there is 
evident accumulation of co-localization of the two proteins at peri-nuclear region. 
However, the signal intensity of the two proteins in the cytosol and focal adhesion sites 
dropped close to basal level (Figure 3.3 B).   
 These results suggest that TMEM184A is an eNOS binding partner. It might serve to 
regulate the activity or translocation of p-eNOS from the region under cell surface to 
perinuclear compartments while TMEM184A is implicated to participate in membrane 
trafficking [59]. Besides binding to eNOS, TMEM184A was also found to co-localize 
with caveolin-1 previously [4] and it is required for heparin signaling [4]. It is possible 
that TMEM184A facilitates the dissociation from caveolin-1 and subsequent 
internalization of the activated eNOS after heparin treatment. Detaching from caveolin-1 
is necessary for activation and the following internalization of p-Ser 1177 eNOS is 
required for the consequent deactivation and desensitization of eNOS. 
 
3.3.4: Integrin involved eNOS activation requires TMEM184A 
Heparin and laminar shear stress have some similar anti-proliferative and anti-
inflammatory responses. Both heparin and laminar shear stress can suppress proliferation 
of endothelial cells and VSMCs [88], and down-regulate p-Erk. Integrin, which is 
involved in mechanosensing, is one of the heparin binding proteins [54]. Integrin is an 
important upstream receptor that can mediate phosphorylation of eNOS, which plays a 
role in heparin signaling. To explore the potential relationship between integrin and 
heparin induced eNOS activation, we examined the level of activated eNOS in both A7r5 
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cells and TMEM184A stable knock down A7r5s in response to RGD and heparin 
treatment. As shown in Figure 3.4, cells treated with heparin and RGD has lower eNOS 
phosphorylation than heparin alone. The level of p-Ser1177 eNOS was significantly 
increased in response to RGD treatment in A7r5 cells and heparin treatment diminished 
this increase, which may be because of potential competition between heparin and RGD 
in interacting with integrin. In TMEM184A stable knockdown cells, there was no evident 
effect of heparin or RGD. It is thus revealed that heparin can interfere with and 
TMEM184A is required in an RGD-integrin-eNOS pathway.  
 
3.3.5: TMEM184A associates with integrin αV 
Results from Figure 3.5 suggest that integrin is involved in heparin signaling pathway. There 
have also been reports about association between heparin and integrin. The ectodomain of 
α5β1 integrin binds to heparin with high affinity [93]. Heparin also binds to αvβ3 integrin 
[93]. To examine whether TMEM184A, which is the receptor of heparin, associates with 
integrin αV, we immunoprecipitated vascular cells proteins with antibodies against NTD of 
TMEM184A and analyzed with antibodies against integrin αV in a western blot. The result 
indicates that TMEM184A associates with integrin αV in vascular cells (Figure 3.5.). 
 
3.3.6: Interactions between Ca2+ and heparin signaling pathway 
Results from Figure 3.6 suggest that heparin activates eNOS. Ca2+ is important in 
activation of eNOS. eNOS activation requires eNOS-calmodulin binding which can be 
triggered by intracellular calcium transients [96]. In addition, Ca2+/CaM complex 
interacts with and regulates a large number of proteins including CaM kinaseII 
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(calcium/calmodolun-dependent protein kinase ii). CaM kinaseII can catalyze 
phosphorylation at ser 1177 of eNOS, which activate eNOS by enhancing affinity 
between calmodulin and eNOS.  
Heparin has been revealed to be a competitive antagonist of IP3 receptors [85]. Heparin 
is found to inhibit the inositol (1,4,5)-trisphosphate (IP3) receptor, which is a classic 
intracellular Ca2+ release channel [85] and a principle signaling protein involved in gap 
junction-mediated propagation of Ca2+ waves [85]. But it is reported that heparin 
treatment (125 IU) results in intracellular Ca2+ release, actives PLCγI and CaMKII, as 
well as inducing NO production [96] while PLCγI is known to be able to produce IP3 and 
induce Ca2+ release. 
In order to investigate if heparin’s activation, which we observed, on eNOS is dependent 
on Ca2+ level and activity of CaM kinaseII, we treated A7r5 cells with EGTA (Ca2+ 
chelator) (Figure 3.6) and KN-93 (CaM kinaseII) inhibitor (Figure 3.6) respectivelly. The 
results indicate that EGTA abolished heparin's effects on eNOS, which indicates that 
extracellular Ca2+ is necessary for the ability of heparin treatment to result in eNOS 
activation. Next, KN-93, a CaM kinase II inhibitor was employed (Figure 3.7) to 
determine whether CaM Kinase II activity was required for the heparin effect. The results 
from Figure 3.7 reveal that inhibiting CaM kinase II reduced the ability of heparin 
treatment to activate eNOS. This implies that CaM kinase II is involved in heparin-
induced activation of eNOS but suggests that calcium has effects on eNOS activation that 
go beyond the activation of CaM Kinase II, consistent with the requirement of calcium 
for direct involvement in eNOS activity. 
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3.3.7: TRPV4’s role in heparin signaling pathway 
Results above suggest that Ca2+ is required in heparin induced activation of eNOS. 
Results from 3.3.6 indicates that the short term calcium wave is extracellular originated, 
potentially through a Ca2+ channel. we used GSK2193874 and RN1734, two inhibitors of 
a membrane Ca2 channel TRPV4, which has been reported to be involved in eNOS’s 
activation in response to Ca2+ transients [110] (Fig 8.). Results showed that one of the 
inhibitors RN1734 reversed heparin’s up-regulation of eNOS while another inhibitor 
GSK2193874 reduced such up-regulation significantly (Fig 8.). These results imply that 
Ca2 wave in response to heparin that activates eNOS is mediated or partially mediated 
through TRPV4. 
 
3.3.8: Akt is not necessary in heparin activated eNOS 
Results for Fig. 5 indicates that Akt is not activated upon heparin treatment. Thus we did 
not do further study to investigate if blocking Akt would affect heparin’s activation on 
eNOS. 
 
3.4: Discussion and future direction 
We here demonstrated that eNOS has an essential role in heparin’s anti-inflammatory 
responses in vascular smooth muscle cells. Our group previously reported that cGMP-
dependent protein kinase (PKG), which is a downstream factor of eNOS is involved in 
heparin down-regulates MAPK activation in vascular smooth muscle cells [4][18]. Our 
previous data revealed that heparin’s receptor TMEM184A co-localizes with caveolin-1 
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in Rat aortic smooth muscle cells and BAOECs [4], which is eNOS’s binding partner. 
This further supports the hypothesis that eNOS potentially plays a role in heparin’s anti-
inflammatory signaling pathway. We reported here that by knocking down eNOS, 
heparin’s inhibition on ERK and ELK-1 activation is abolished, which provides evidence 
for this hypothesis.  
We showed that in response to heparin treatment, eNOS’s activity and sub-cellular 
translocation is altered. Phosphorylation of eNOS on Ser1177 was induced by heparin 
treatment as early as 3 min and dropped to basal level after 30 min, which extend the 
finding by Kouretas et al. [111], who showed that heparin and its derivative, N-acetyl 
heparin, increase eNOS activity, determined by citrulline and nitric oxide (NO) 
metabolite formation.  
We also demonstrated that eNOS activation upon heparin treatment is dependent on 
heparin receptor TMEM184A by knocking down TMEM184A.  
Our work also reveals that phosphorylated eNOS accumulated at cell membrane and 
focal adhesion sites upon heparin treatment and subsequently co-translocated with 
TMEM184A to perinuclear region. This suggest that TMEM184A may be a eNOS 
binding partner. It might serve to regulate the activity or translocation of p-eNOS from 
the region under cell surface to perinuclear compartments while TMEM184A is 
implicated to participate in membrane trafficking in mouse germ cells [59]. Besides 
binding to eNOS, TMEM184A was also found to co-localize with caveolin-1 in Rat 
aortic smooth muscle cells and BAOECs previously [4] and it is required for heparin 
signaling responses in A7r5 cells [4]. It is possible that TMEM184A facilitates the 
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dissociation from caveolin-1 and subsequent internalization of the activated eNOS after 
heparin treatment. Detaching from caveolin-1 is necessary for activation and the 
following internalization of p-Ser 1177 eNOS is required for the consequent deactivation 
and desensitization of eNOS. 
Given the result that activated eNOS accumulated at focal adhesion sites with TMEM184 
after heparin treatment and the following facts we hypothesized that integrin might be 
involved in heparin, eNOS and TMEM184A signaling pathway.  
We presented that TMEM184A co-translocated with eNOS in response to heparin while 
it was necessary in heparin’s up-regulation of eNOS in A7r5 cells. We also note that 
TMEM184A co-localized with caveolin-1. However, these did not demonstrate how the 
transmembrane protein TMEM184A transmits the signal from heparin stimulation to 
intracellular factors. We hypothesized that there might be membrane proteins associated 
with TMEM184A to affect or induce heparin signaling. Several proteins including 
integrin, gal-3, VE-cadherin have potential to bind with TMEM184A and participate in 
heparin signaling as illustrated below. As mentioned above in background, heparin's anti-
inflammatory and anti-proliferation signaling pathway share some players with laminar 
shear stress response. For example, laminar shear stress and heparin can both reduce 
smooth muscle cell proliferation and activity ERK1/2 (and Akt). And they modulate the 
alignment and morphology in similar way according to previous data of our lab. Thus, it 
is reasonable to predict heparin and its potential receptor TMEM184A have interactions 
with or play roles in mechanotransduction processes by interacting with some classic 
members of mechanotransduction signaling system.  
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There are facts indicating integrin might be one of those members. First integrin is vital 
in the mechanosensing complex and secondly it is an upstream factor of Akt, eNOS and 
ERK1/2. In addition, integrins are present in both ECs and SMCs. There are also 
published results showing that up-regulation of HSPG synthesis induced by heparin in 
endothelial cells is dependent on the interaction of heparin with integrin while RGD 
peptide abolishes the effect [96]. This up-regulation was also associated with the 
phosphorylation of focal adhesion proteins and Ras/Raf/MEK/ERK MAP and Ca2+ /NO 
pathways which are downstream signaling factors of integrins confirmed by using 
inhibitors of Ras, MEK, NOS. Besides the relevance in signaling events between integrin 
and TMEM184A, there are also many reports for interactions between integrin and 
caveolin. For example, β1 Integrin/caveolin-1 mechano-signaling complex responds to 
shear stress and lead to RhoA and actin remodeling in Bovine aortic endothelial cells 
[112]. β1 integrin endocytosis is dependent on caveolin- 1 in myofibroblasts [106]. There 
have been reports about association between heparin and integrin. The ectodomain of 
α5β1 integrin binds to heparin with high affinity in endothelial cells (KD = 15.5 nM) 
[93]. Heparin also binds to αvβ3 integrin in endothelial cells [93]. There is also evidence 
suggesting that integrin controls localization of CEMMs [107] at the plasma membrane 
of epithelial cells to regulate cellular processes [108]. Based on our previous data that 
TMEM184A co-localizes with caveolin-1 [4], it is possible that TMEM184A also 
interacts with integrin in caveolae or lipid rafts. Therefore, we hsypothesized that integrin 
might interact with TMEM184A to interfere with eNOS’s binding with caveolin-1 in 
response to heparin.  
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Our work demonstrated that integrin was involved in heparin’s regulation of eNOS while 
TMEM184A was required for the regulation. We also showed that TMEM184A co-
localized with integrin αV. We also ran co-IP for integrin β1 and TMEM184A but such 
co-localization was not seen. Future research may determine the role of different types of 
integrin subunits. The results showed that RGD itself significantly activated eNOS 
however diminished heparin’s activation on eNOS. This may be because RGD itself, as 
an integrin binding motif, may activate integrin as well as compete and impede heparin 
induced integrin’s binding to its agonists. Heparin blocks RGD induced eNOS activation.   
eNOS is regulated through various cellular events including post-translational 
modification, calcium wave stimulation, association or dissociation with its binding 
proteins. Given that heparin elevated eNOS activity shortly after treatment, we 
hypothesized that calcium stimulation might be involved in eNOS activation by heparin. 
Intracellular Ca2+ increases can cause calmodulin binding to eNOS and hence facilitate 
electron transfer from the reductase domain to the oxygenase domain of the NOS to 
synthesize NO [26]. Besides facilitating electron transfer, Ca2+/calmodulin complex can 
also activate CaM kinaseII to phosphorylate eNOS. We used CaM kinaseII inhibitor KN-
93 and showed that CaM kinaseII may be partially involved in eNOS’s activation by 
heparin because KN-93 decreased the activation but did not abolish it. We showed that 
EGTA inhibited heparin’s activation of eNOS, which suggests that Ca2+ is essential for 
phosphorylation of eNOS upon heparin treatment by 10 min. However, it did not prove 
the source of Ca2+ that activates eNOS because EGTA only eliminated extracellular Ca2+ 
from the cell media to reduce Ca2+ concentration. But based on that fact that heparin 
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activates eNOS as early as 3min, we hypothesize that extracellular Ca2+ plays a role in 
short term activation of eNOS by heparin. We cannot exclude the possibility that eNOS 
was also activated by intracellular Ca2+ release in long term, which has been implicated 
in heparin induced signaling events. Considering that eNOS activation is fast in response 
to heparin treatment, we decided to explore transmembrane Ca2+ channels. We used two 
inhibitors GSK2193874 and RN1734 of TRPV4 instead of using only one inhibitor 
because the effect of the various TRPV4 are different according to reports. The results we 
obtained showed that RN1734 reversed heparin’s effect on eNOS while another inhibitor 
GSK2193874 only reduced such up-regulation. Given that GSK2193874 is a potent 
antagonist of TRPV4 channels that reported to be not as effective as some of other 
antagonist [113]. We think the results still support that TRPV4 may play a role in 
heparin’s activation on eNOS.  
One of the eNOS activating mechanisms besides intracellular calcium mobilization, the 
PI3K/Akt cascade also assists in eNOS activation. Upon activation, Akt can 
phosphorylate eNOS at ser1177, which enhances affinity between eNOS and calmodulin 
and promotes electron transfer and upregulate activity of eNOS [30]. In response to shear 
stress, Ca2+ activated PI3K/Akt pathway leads to phosphorylation of eNOS at Ser1177 
and consequently contributes to maintain basal vascular tone in endothelial cells [28]. We 
also performed experiments on Akt but there was no sound evidence to support Akt’s 
function in heparin’s up-regulation on eNOS. 
It is hypothesized that the direct binding between heparin/heparan sulfate and integrins is 
required for the localization of endostatin in endothelial cell lipid rafts [93]. Endostatin is 
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a C-terminal fragment derived from type XVIII collagen. It is an angiogenesis inhibitor 
and found to block growth factors such as VEGF mediating pro-angiogenic action [95]. 
The stimulation of HSPG synthesis and sulfation pattern modification are found to be 
mediated by interaction between heparin and integrin while RGD peptides block such 
effects in endothelial cells [96]. And this upregulation is associated with phosphorylation 
of focal adhesion proteins, MAPK pathways, and NO pathways in endothelial cells [96]. 
Based on this evidence, integrin might be involved in heparin signaling through a 
mechanosensing based mechanism such as cross activation of RTKs and their 
downstream signaling effectors or possibly through its binding with heparin to control 
localization of endostatin to suppress proliferation. 
Several proteins including integrin, gal-3, VE-cadherin have potential to bind with 
TMEM184A and participate in heparin signaling as illustrated below. As mentioned 
above in background, heparin's anti-inflammatory and anti-proliferation signaling 
pathway share some players with laminar shear stress response. For example, laminar 
shear stress and heparin can both reduce SMC proliferation and activity ERK1/2 (and 
Akt). And they modulate the alignment and morphology in similar way according to 
previous data of our lab. As illustrated in Chapter 3, integrin plays a role in TMEM184A 
mediated heparin signaling in rat smooth muscle cells. Heparin and its receptor 
TMEM184A may also have interactions with or play roles in mechanotransduction 
processes by interacting with integrin, which is one of the classic members of 
mechanotransduction signaling system. 
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Another member of mechanosensor complex, VE-cadherin, also worth investigation. 
Earlier data from the lab indicates that TMEM184A directly or indirectly associates with 
VE-cadherin in BAOECs. VE-cadherin can serve as adaptor between PECAM and 
VEGFR and form a complex that lead to integrin activation and other events [114]. 
Besides αv, we also investigated β3’s interaction with TMEM184A. Antibodies to 
integrin αvβ3 or αvβ5 but not β1 abolish the mechanical strain induced mitogenic 
response in VSMCs [74]. Integrin αvβ3 is also a major galectin-3–binding protein while 
antibodies that blocks αvβ3 integrin's function significantly inhibited the galectin-3–
induced angiogenesis. In SMCs, the occupancy of the heparin binding domain of αvβ3 
ligand is necessary for proliferative effects of IGF-1 including phosphorylation of ERK 
[115]. These facts suggest that αvβ3 integrin is an interesting protein to investigate 
regarding its involvement in TMEM184A and heparin signaling. It has been reported that 
association between some types of integrin and gal-3 induced angiogenic response while 
gal-3 promoted clustering of the integrins and activated FAK. And MAPK/ERK1/2 
pathway is also mediating gal-3 signaling events. Thus, it worth hypothesizing that 
heparin treatment might disrupt or enhance binding between integrin and gal-3 since 
heparin can both bind to integrin and gal-3. The disruption might hinder or improve 
either integrin signaling or gal-3 signaling. 
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3.5: Figures 
 
3.1 Knockdown of eNOS eliminates heparin responses in A7r5 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
A. A7r5 cells transfected with siRNA against eNOS or control siRNA were treated with 200 
μg/ml heparin for 10 min followed by fixation with ice-cold MeOH. Cells were stained for 
eNOS (sc-376751). Scale bars = 50 μm. At least 100 cells in three separate experiments were 
analyzed for each condition. *** p<0.005 B. Identical cells were prepared as in A. Images of 
cells stained for pERK are representative of three independent experiments. Scale bars = 10 
μm. At least 50 cells per condition in each individual experiment were analyzed for 
phosphorylated Erk. **, p < 0.0001. C. A7r5 cells (NT), eNOS siRNA transfected A7r5 cells 
and control siRNA transfected A7r5 cells were treated with heparin for 10 min followed by 
PDGF stimulation. Cells were stained for pELK, ***, p < 0.0001 heparin/PDGF compared to 
PDGF. Scale bars = 50 μm. The graph represents data from three independent experiments 
with at least 50 cells analyzed per condition in each experiment.  
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3.2 TMEM184A knockdown A7r5 cells do not show heparin-induced increase in p-
Ser 1177 eNOS 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
A. A7r5 cells and stable TMEM184A A7r5 knockdown cells were treated with 200 
μg/ml heparin for the indicated times followed by fixation and staining for p-
eNOS. Images are representative of three independent experiments. Scale bars = 
50 μm. B. A7r5 cells and TMEM184A stable knockdown cells were treated with 
heparin as in A. At least 50 cells per condition (from three separate experiments) 
were evaluated for p-eNOS. ***, p < 0.0001. 
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3.3 eNOS co-localize under quiescent state and co-translocate with TMEM184A 
after heparin treatment in VSMCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A, eNOS. Membrane protein samples of BAOEC lysates were incubated with the eNOS 
antibody, precipitated using EZview affinity beads, or beads alone(B) and developed 
using INT TMEM184A antibody. IB, immunoblot. The blot is representative of 2 
separate experiments. B, A7r5 cells were incubated with 200 μg/ml heparin for the 
indicated times and fixed by 4% PFA. Images are representative of two separate 
experiments. Scale bars = 10 μm. 
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3.4 Heparin interferes with and TMEM184A mediates RGD-integrin-eNOS 
pathway 
A 
 
B 
 
 
 
A, A7r5 cells and stable knockdown for TMEM184A A7r5 cells were treated with or 
without 200 μg/ml heparin only or after RGD pre-treatment followed by fixation with 4% 
PFA. Images are representative of three independent experiments. Scale bars = 10 μm. B, 
A7r5 cells were treated with heparin and RGD as in A. At least 50 cells per condition 
were examined in each repeat for phosphorylated eNOS. ***, p < 0.0001.  
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3.5 Immunoprecipitation of TMEM184A detects integrin alpha V but not beta 3 
subunit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A7r5 cells were harvested for immunoprecipitation (IP). Membrane samples from cell 
lysates were incubated with TMEM184A, precipitated using EZview affinity beads, or 
beads alone(B) and developed using integrin αV and beta 3 antibody. IB, immunoblot. 
The blot is representative of 2 separate experiments. 
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3.6 EGTA abolished heparin induced activation of eNOS 
A                                              B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A, A7r5 cells preincubated with or without EGTA were treated with or without 200 μg/ml 
heparin followed by fixation with 4% PFA. Images are representative of three 
independent experiments. Scale bars = 50 μm. B, A7r5 cells were treated with heparin 
and EGTA as in A. At least 50 cells per condition were examined in each repeat for 
phosphorylated eNOS. ***, p < 0.0001.  
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3.7 KN-93 decreased heparin induced activation of eNOS 
 
                                                                           B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A, A7r5 cells preincubated with or without KN-93 were treated with or without 200 
μg/ml heparin followed by fixation with 4% PFA. Images are representative of three 
independent experiments. Scale bars = 50 μm. B, A7r5 cells were treated with heparin 
and KN-93 as in A. At least 50 cells per condition were examined in each repeat for 
phosphorylated eNOS. ***, p < 0.0001.  
 
 
 
 
A 
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3.8 TRPV4 inhibitors decreased heparin-induced activation of eNOS. 
A                                C 
 
 
 
 
 
 
 
B                             D 
 
 
 
 
 
 
 
A and B., A7r5 cells preincubated for 30 min with or without RN1734 were treated with 
or without 200 μg/ml heparin followed by fixation and staining for p-eNOS. Images are 
representative of three independent experiments. Scale bars = 50 μm. C and D. A7r5 
cells were treated with GSK and heparin as in A and B. At least 50 cells per condition 
were examined for phosphorylated eNOS in each repeat. **, p < 0.0001, heparin vs. 
without heparin. 
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3.9 Heparin does not significantly change activity of Akt in A7r5 cells 
 
 
 
 
 
A7r5 cells were treated with 200 μg/ml heparin followed by fixation with 4% PFA and 
staining for active Akt. Images are representative of three independent experiments. Scale 
bars = 50 μm. 
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Chapter 4: Conclusions and Future Directions 
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4.1 Conclusions 
We identified the heparin receptor TMEM184A by using Monoclonal heparin binding 
blocking antibodies. We also examined the hypothesis that eNOS has an essential role in 
heparin’s anti-proliferation responses in VSMCs. Our group previously reported that 
cGMP-dependent protein kinase, which is a downstream factor of eNOS, is involved in 
heparin-induced down-regulation of MAPK activation in VSMCs [18]. Our finding that 
heparin’s receptor, TMEM184A, co-localizes with caveolin-1, which is eNOS’s binding 
partner, also supports the hypothesis that eNOS plays a role in heparin’s anti-proliferative 
signaling pathway. We report here that by knocking down eNOS, inhibition of ERK and 
Elk-1 activation typically induced by heparin is abolished, a finding which provides 
evidence supporting this hypothesis.  
To further support the hypothesis, we determined that in response to heparin treatment, 
eNOS’s activity and sub-cellular translocation are altered. Phosphorylation of eNOS on 
Ser1177 was induced by heparin treatment as early as 3 min and dropped to basal levels 
after 30 min. These data are consistent with earlier results indicating that heparin 
treatment can preserve NOS activity in damaged tissue [20]. Crucially, we demonstrated 
that eNOS activation upon heparin treatment is dependent on heparin receptor 
TMEM184A by knocking down TMEM184A.  
Our work also reveals that phosphorylated eNOS is initially found at cell membrane and 
focal adhesion sites upon heparin treatment and subsequently moved with TMEM184A 
to the peri-nuclear region. This result coupled with co-immunoprecipitation suggests that 
TMEM184A may be an eNOS binding partner that serves to regulate the activity or 
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translocation of p-eNOS from the regions adjacent to the cell surface to perinuclear 
compartments. These results are consistent with published evidence on TMEM184A, 
which implicated TMEM184A in membrane trafficking [59]. Besides binding to eNOS, 
TMEM184A also co-localizes with cav-1 and is required for heparin signaling responses 
[4]. It is possible that TMEM184A facilitates the dissociation from cav-1 and subsequent 
internalization of the activated eNOS after heparin treatment. Detachment from cav-1 is 
necessary for activation [116] and the following internalization of p-Ser1177 eNOS is 
required for the consequent deactivation and desensitization of eNOS.  
There are many reports indicating interactions between integrin and cav-1. For example, 
β1 Integrin/cav-1 mechano-signaling complex responds to shear stress and leads to RhoA 
and actin remodeling in endothelial cells [105]. β1 integrin endocytosis is dependent on 
cav- 1 in myofibroblasts [106]. There have been reports of association between heparin 
and integrin. The ectodomain of α5β1 integrin binds to heparin with high affinity in 
endothelial cells (KD = 15.5 nM) [117]. Heparin also binds to αvβ3 integrin in 
endothelial cells [118]. There is also evidence suggesting that integrin controls 
localization of cholesterol-enriched membrane microdomains [96] at the plasma 
membrane of epithelial cells to regulate cellular processes [108]. Based on our previous 
data that TMEM184A co-localizes with cav-1 [4], it is possible that TMEM184A also 
interacts with integrin in caveolae or lipid rafts. Several proteins including integrin, gal-3, 
and VE-cadherin have a potential to also associate with TMEM184A and participate in 
heparin signaling. Heparin's anti-inflammatory and anti-proliferation signaling pathways 
share some players with laminar shear stress response. For example, laminar shear stress 
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and heparin can both reduce VSMC proliferation and ERK1/2 activity. Thus, it is 
reasonable to hypothesize that heparin and its receptor TMEM184A have interactions 
with or play roles in mechanotransduction processes by interacting with one or more 
members of mechanotransduction signaling system.  
Integrin is vital in the mechanosensing complex and secondly it is an upstream factor of 
Akt, eNOS and ERK1/2. In addition, integrins are present in both ECs and VSMCs. 
There are also published results showing that up-regulation of HSPG synthesis induced 
by heparin in endothelial cells is dependent on the interaction of heparin with integrin 
while RGD peptide abolishes the effect [96]. This up-regulation is also associated with 
the phosphorylation of focal adhesion proteins and Ras/Raf/MEK/ERK MAPK and Ca2+ 
/NO pathways that are downstream signaling factors of integrins confirmed by using 
inhibitors of Ras, MEK, NOS. Therefore, we hypothesized that integrin might interact 
with TMEM184A to interfere with eNOS’s binding with cav-1 in response to heparin.  
Our finding of activated eNOS in what appeared to be focal adhesions further supported 
the hypothesis of integrin involvement in the heparin/TMEM184A induced eNOS 
activation. Our results demonstrate support for this hypothesis. In addition to the 
localization of pSer 1177 eNOS at focal adhesions, immunoprecipitation with anti-
TMEM184A antibodies pulled αV integrin along, though similar results were not seen 
using probes for β1 integrin. As expected, RGD treatment resulted in eNOS activation in 
a pattern similar to heparin-induced activation. However, such treatment with either 
heparin or RGD in TMEM184A knockdown cells did not result in eNOS activation. Most 
intriguingly, heparin treatment coupled with RGD did not result in eNOS activation. 
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Whether heparin interferes with RGD binding, or whether structural changes induced by 
either heparin or RGD cannot occur when both heparin and RGD are present, further 
studies are needed to determine the inter-relationships between these various players. 
Evidence suggests that the eNOS pathway in endothelial cells has important effects at 
focal adhesions including cGMP-dependent protein kinase regulation of migration and 
focal adhesion sites [119] and NO induced modulation of focal adhesions [120].  
eNOS is regulated through various cellular events including post-translational 
modification, calcium wave stimulation, association or dissociation with its binding 
proteins. In addition, shear stress induces phosphorylation of endothelial eNOS through a 
PI3-kinase Akt pathway [89][77]. We evaluated the possibility that Akt was activated and 
then phosphorylated eNOS, but we found no evidence of changes in Akt activity in the 
period consistent with heparin effects (Fig 4.3.9). Given that heparin elevated eNOS 
activity shortly after treatment, we hypothesized that calcium stimulation might be 
involved in eNOS activation in response to heparin. Intracellular Ca2+ increases can cause 
calmodulin binding to eNOS and hence facilitate electron transfer from the reductase 
domain to the oxygenase domain of the NOS to synthesize NO [96]. Heparin treatment 
results in intracellular Ca2+ release, actives PLCγI and CaMKII, as well as inducing NO 
production [96] since PLCγI produces IP3 and induces Ca2+ release. Besides facilitating 
electron transfer, Ca2+/calmodulin complexes can also activate CaMKII to phosphorylate 
eNOS. Initial studies found that EGTA inhibited heparin-induced eNOS activation, which 
suggests that Ca2+ is essential for heparin’s effect on eNOS. EGTA eliminated 
extracellular Ca2+ from the cell media to reduce Ca2+ concentration suggesting that 
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extracellular Ca2+ is required for initial eNOS activation. We cannot exclude the 
possibility that eNOS was also activated by intracellular Ca2+ release in the longer term. 
We used CaMKII inhibitor KN-93 and showed that CaMKII is involved in eNOS’s 
activation by heparin because KN-93 decreased, but did not abolish, the activation. It is 
likely that both calcium/calmodulin binding to eNOS and CaMKII phosphorylation are 
involved in the response.  
Considering that eNOS activation is fast in response to heparin treatment, and eliminating 
extracellular Ca2+ blocked immediate heparin-induced responses, we decided to explore 
transmembrane Ca2+ channels. A TRPV4/ Ca2+-mechanism of eNOS activation was 
recently identified in endothelial cells [110]. There is an ATP-dependent TRPV4 
activation coupled with an eNOS feedback mechanism in the endothelial system that 
limits the extent of activation. Another recent study identified a role for TRPV4 in fluid 
shear stress in endothelial cells with a specific localization in small clusters at the basal 
membrane [121]. We used TRPV4 inhibitors GSK2193874 and RN1734. The results we 
obtained using RN1734, a very commonly employed inhibitor, showed a reversal of 
heparin’s effect on eNOS, consistent with TRPV4 playing a role in heparin-induced 
eNOS activation. The inhibitor GSK2193874 only reduced such up-regulation, and 
resulted in increased basal eNOS phosphorylation. The reason for different responses to 
the two TRPV4 inhibitors is not clear, but could possibly be due to TRPV4 interacting 
proteins, differently influencing effects of the two inhibitors. Overall, our results support 
the idea that TRPV4 plays a role in heparin’s activation of eNOS through facilitating 
calcium transients required for eNOS phosphorylation. Additional studies will be 
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required to determine how the heparin-TMEM184A-TRPV4 activation mechanism works, 
but this system is consistent with the rapid activation of eNOS identified in our studies.  
Immunoprecipitation in endothelial cells using heparin-receptor MAbs identified the 
target protein as TMEM184A [4]. In cell lines including RAOSMCs and BAOECs, the 
putative heparin receptor TMEM184A co-localizes with cav-1, which is one of the most 
important eNOS associating proteins that regulates activity of eNOS [4]. Here we report 
that heparin interactions with TMEM184A result in activation of eNOS through Ca2+-
dependent phosphorylation at Ser 1177. These results provide additional evidence linking 
mechano-signaling and heparin-induced signaling pathways. In addition, they suggest 
intriguing next steps in our exploration of heparin signaling mechanisms.  
In addition to facilitating Ca2+-induced phosphorylation, it is possible that after heparin 
treatment, TMEM184A acquires the ability to interfere with eNOS’s binding with its 
binding partners such as cav-1 and subsequently activates eNOS. Alternatively, 
TMEM184A might alter eNOS’s activity by regulating its sub-cellular translocation and 
life cycle since TMEM184A has been reported to be involved in membrane trafficking 
[59]. Additional studies will be necessary to examine the possible roles for TMEM184A 
in trafficking of eNOS. What is now clear is that heparin interactions with TMEM184A 
play a role in activation of eNOS through increases in intracellular Ca2+ and Ca2+-induced 
phosphorylation of eNOS. 
 
4.2 Signal Model 
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Figure 4.1 Predicted signal pathway for heparin-TMEM184A signaling pathway. The figure 
shows the signaling from heparin-TMEM184A binding to the activation of eNOS and decrease in 
p-ERK level. 
 
4.3 Future Directions 
4.3.1 Integrin in Heparin Signaling 
Our work demonstrated that integrin was involved in heparin’s regulation of eNOS while 
TMEM184A was required for the regulation. However, the detailed integrin related 
signaling events during the regulation process is not clear. 
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It is hypothesized that the direct binding between heparin/heparan sulfate and integrins is 
required for the localization of endostatin in endothelial cell lipid rafts ([118]. Endostatin 
is a C-terminal fragment derived from type XVIII collagen. It is an angiogenesis inhibitor 
and found to block growth factors such as VEFG mediating pro-angiogenic action [95]. 
The stimulation of HSPG synthesis and sulfation pattern modification are found to be 
mediated by interaction between heparin and integrin while RGD peptides block such 
effects [96]. And this upregulation is associated with phosphorylation of focal adhesion 
proteins, MAPK pathways, and NO pathways [96]. Based on this evidence, integrin 
might be involved in heparin signaling through a mechanosensing based mechanism such 
as cross activation of RTKs and their downstream signaling effectors or possibly through 
its binding with heparin to control localization of endostatin to suppress proliferation. 
Antibodies to integrin αvβ3 or αvβ5 but not β1 abolish the mechanical strain induced 
mitogenic response in VSMCs [122]. Integrin αvβ3 is also a major galectin-3–binding 
protein while antibodies that block αvβ3 integrin's function significantly inhibited the 
galectin-3–induced angiogenesis. In SMCs, the occupancy of the heparin binding domain 
of αvβ3 ligand is necessary for proliferative effects of IGF-1 including phosphorylation 
of ERK [115]. It has been reported that association between some types of integrin and 
gal-3 induced an angiogenic response while gal-3 promoted clustering of the integrins 
and activated FAK. And MAPK/ERK1/2 pathway is also mediating gal-3 signaling 
events. Thus, it worth hypothesizing that heparin treatment might disrupt or enhance 
binding between integrin and gal-3 since heparin can both bind to integrin and gal-3. The 
disruption might hinder or improve either integrin signaling or gal-3 signaling. 
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4.3.2 Rab11 and TMEM184A in Intracellular Recycling 
The RAB11 family of GTPases is found in post-Golgi membranes, perinuclear recylcing 
endosomes. It is well known in regulating [123] endocytosed cargos. It is also revealed to 
regulate vesicle exocytosis at plasma membrane [123]. Rab11 is commonly used as a 
marker for Perinuclear recycling compartment, which located in juxtanuclear region and 
need Rab11 for its function and morphology. Many endocytosed recptors such as 
integrins are delivered here before recycling back to plasma membrane [67]. Rab11 is 
involved in building motor protein complexes [122] and transporting of recycling 
endosomes [68]. Based on the fact that TMEM184A co-localizes with eNOS at 
perinuclear regions and it is highly suspected in membrane trafficking, it is reasonable to 
see if TMEM184A co-localize or interacts with Rab11.  
It is not clear if the TMEM184A at perinuclear region is under recycling between plasma 
membrane and ERC or is just synthesized and transported to Golgi. In order to answer 
this question, sub-cellular distribution GFP-TMEM184A can be monitored either by 
fixation at different time points or live cell imaging while blocking new protein synthesis 
with cycloheximide after 48 hrs of expression. If TMEM184A is not involved in 
recycling, there should be a decrease of TMEM184A at perinuclear region after a period 
of time while many of them still can be seen on plasma membrane. Alternatively, the 
expressed TMEM184A can be tracked to see if those delivered to plasma membrane after 
expression will be internalized and go back to membrane again. If TMEM184A is proved 
to be part of the recycling process, further experiments are to be done to see if adding 
heparin is affecting the recycling process. 
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Activities and distributions of integrin can be regulated by its internalization and 
recycling. For example, a Rab11 dependent pathway can increase recycling of α5β1 
integrin and triggers activation of ROCK and inactivation of cofilin [67]. As mentioned 
above, TMEM184A might interact with integrin and they might associate with each other 
in caveolae. If TMEM184A participate in recycling, it is possible that it regulates 
recycling of integrin or conversely.  
The work illustrated in this dissertation provide a potential model that TMEM184A might 
work with transmembrane proteins to transduce heparin signal into intracellular signaling 
pathways, triggering Ca2+ flows, activating eNOS and subsequently down regulates p-
ERK and p-ELK. It further reveals TMEM184A’s role in regulating heparin signaling 
based on what was reported earlier by our lab. 
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